First-in-Humans PET Imaging of Tissue Factor in Patients with Primary and Metastatic Cancers Using $^{18}$F-labeled Active-Site Inhibited Factor VII ($^{18}$F-ASIS): Potential as Companion Diagnostic

Mathias Loft*1, Camilla Christensen*1, Malene M. Clausen1,2, Esben A. Carlsen1, Carsten P. Hansen3, Niels Kroman4, Seppo W. Langer2,5, Claus Hogdall6, Jacob Madsen1, Nic Gillings1, Carsten H. Nielsen1,7, Thomas L. Klausen1, Søren Holm1, Annika Loft1, Anne K. Berthelsen1, and Andreas Kjaer1

1Department of Clinical Physiology and Nuclear Medicine & Cluster for Molecular Imaging, Copenhagen University Hospital – Rigshospitalet & Department of Biomedical Sciences, University of Copenhagen, Denmark; 2Department of Oncology, Copenhagen University Hospital – Rigshospitalet, Denmark; 3Department of Surgery, Copenhagen University Hospital – Rigshospitalet, Denmark; 4Department of Breast Surgery, Copenhagen University Hospital – Rigshospitalet, Denmark; 5Department of Clinical Medicine, University of Copenhagen, Denmark; 6Department of Gynecology, Copenhagen University Hospital – Rigshospitalet, Denmark and 7Minerva Imaging ApS, Denmark

P

Personalized medicine based on targeted therapies is predicted to shape the future of oncology in the coming decades. An emerging oncologic target is the transmembrane glycoprotein tissue factor (TF) that functions as the main initiator of the extrinsic coagulation cascade (1). In addition to its role in coagulation, TF expression is also linked to several cancer hallmarks including tumor growth, angiogenesis, and metastatic potential (2,3). Abundant TF expression has been reported in most solid tumors, and TF expression levels are associated with disease stage and overall survival in pancreatic cancer (4), cervical cancer (5), non–small-cell lung cancer (6–8), and breast cancer (9).

TF-targeted therapies are currently under translation into the clinical treatment of cancer patients. In 2019, reports from the first phase 1–2 clinical trial of the TF-targeted antibody–drug conjugate tisotumab vedotin in patients with recurrent, advanced, or metastatic solid tumors showed an objective tumor response in 16% of the patients (10). Recently, a 24% response rate was demonstrated in a phase 2 trial in previously treated recurrent or metastatic cervical cancer patients (11), and the U.S. Food and Drug Administration approved the therapy in September 2021 for this indication (12).

With the emergence of TF-targeted therapies, robust methods for quantifying TF expression in primary tumors and metastases are needed for efficient patient selection and stratification. Whole-body PET imaging can reduce the risk of sampling error from within tumor and between tumor heterogeneity seen in ex vivo analyses of tumor biopsies (13). Hence, PET imaging of TF expression is attractive as a companion imaging diagnostic agent for identifying patients eligible for TF-targeted therapies and may have the potential to increase response rates.

Received Mar. 4, 2022; revision accepted May 10, 2022.
For correspondence or reprints, contact Andreas Kjaer (akjaer@sund.ku.dk).
*Contributed equally to this work.
Published online May 19, 2022.
COPYRIGHT © 2022 by the Society of Nuclear Medicine and Molecular Imaging.

Key Words: active site inhibited factor VII (ASIS); tissue factor; PET/CT; first-in-humans; phase I clinical trial

J Nucl Med 2022; 63:1871–1879
DOI: 10.2967/jnumed.122.264068

Tissue factor (TF) expression in cancers correlates with poor prognosis. Recently, the first TF-targeted therapy was approved by the U.S. Food and Drug Administration for cervical cancer. To unfold the potential of TF-targeted therapies, correct stratification and selection of patients eligible for treatments may become important for optimization of patient outcomes. TF-targeted PET imaging based on $^{18}$F-radiolabeled active-site inhibited versions of the TF natural ligand coagulation factor VII ($^{18}$F-ASIS) has in preclinical models convincingly demonstrated its use for noninvasive quantitative measurements of TF expression in tumor tissue. $^{18}$F-ASIS PET imaging thus has the potential to act as a diagnostic companion for TF-targeted therapies in the clinical setting.

Methods: In this first-in-humans trial, we included 10 cancer patients (4 pancreatic, 3 breast, 2 lung, and 1 cervical cancer) for $^{18}$F-ASIS PET imaging. The mean and SD of administered $^{18}$F-ASIS activity was $157\pm35$ MBq (range, 93–198 MBq). PET/CT was performed after 1, 2, and 4 h. The primary objectives were to establish the safety, biodistribution, pharmacokinetics, and dosimetry of $^{18}$F-ASIS. Secondary objectives included quantitative measurements of SUVs in tumor tissue with PET and evaluation of the correlation (Pearson correlation) between tumor SUV$_{\text{max}}$ and ex vivo TF expression in tumor tissue.

Results: Administration of $^{18}$F-ASIS was safe, and no adverse events were observed. No clinically significant changes in vital signs, electrocardiograms, or blood parameters were observed after injection of $^{18}$F-ASIS. Mean $^{18}$F-ASIS plasma half-life was $3.2\pm0.6$ h, and the radiotracer was predominantly excreted in the urine. For injection activity of 200 MBq of $^{18}$F-ASIS, effective whole-body dose was 4 mSv and no prohibitive organ-specific absorbed doses were found. Heterogeneous radiotracer uptake was observed across patients and within tumors. We found a trend of a positive correlation between tumor SUV$_{\text{max}}$ and ex vivo TF expression ($r=0.84, P=0.08, n=5$).

Conclusion: $^{18}$F-ASIS can be safely administered to cancer patients for PET imaging of TF expression in tumors. The trial marks the first test of a TF-targeted PET radiotracer in humans (first-in-class). The findings represent important first steps toward clinical implementation of $^{18}$F-ASIS PET imaging of TF expression.
We have developed a TF-targeted PET radiotracer based on the natural ligand, factor VII (FVII). When vascular injury occurs, FVII is activated to FVIIa by the exposed TF on the endothelial cells and sets off the coagulation cascade. Through inhibition of the active site in FVIIa, the resulting active-site inhibited FVIIa (ASIS) binds to TF with an affinity approximately 5-fold higher than FVIIa without activating the coagulation system. For TF-targeted PET imaging, ASIS is radiolabeled with N-succinimidyl 4-[18F]fluorobenzoate (18F-SFB) to form 18F-ASIS. Preclinical studies with xenograft tumor-bearing mice have demonstrated high and specific 18F-ASIS uptake in tumor tissue that reflects the level of TF expression determined ex vivo. Spurred on by the promising preclinical results, we moved forward with the clinical translation of 18F-ASIS PET imaging to cancer patients.

Here we report our first-in-humans trial on 18F-ASIS PET in cancer patients. The primary objectives were to demonstrate the safety, biodistribution, pharmacokinetics, and dosimetry of 18F-ASIS. As a secondary objective, we investigated radiotracer accumulation in tumors with PET and its correlation with TF expression in ex vivo analyses of matched tumor samples.

MATERIALS AND METHODS

Study Design

We performed the study as an open-label, phase 1 clinical trial approved by the Danish Medicines Agency (EudraCT no. 2015-005583-42) and the Ethical Committee of the Capital Region of Denmark (protocol H-18015477). Patients signed a written informed consent form before inclusion. The study was conducted in accordance with the requirements for good clinical practice including independent monitoring by the Good Clinical Practice of the Danish Medicines Agency (EudraCT no. 2015-005583-42) and the Ethical Committee of the Capital Region of Denmark (protocol H-18015477). Patients signed a written informed consent form before inclusion. The study was conducted in accordance with the requirements for good clinical practice including independent monitoring by the Good Clinical Practice unit of Copenhagen University Hospital, and the trial was registered at ClinicalTrials.gov (NCT03790423). Eligible patients were 18 y or older; diagnosed with breast, lung, pancreatic, cervical, or ovarian cancer; and capable of understanding the patient information in Danish and giving full informed consent. Exclusion criteria were pregnancy/breastfeeding, weight above 140 kg, or history of allergic reaction attributable to compounds of similar chemical or biologic composition to 18F-ASIS.

From January to November 2019, after giving informed consent, 10 patients with pancreatic cancer (n = 4), breast cancer (n = 3), lung cancer (n = 2), and cervical cancer (n = 1) were included in the study and referred to a 18F-ASIS PET/CT imaging series. The mean and SD of the administered mass of 18F-ASIS was 0.67 ± 0.12 mg (range, 0.41–0.84 mg). The mean administered activity was 157 ± 35 MBq (range, 93–198 MBq), yielding a mean specific activity of 245 ± 84 MBq/mg (range, 126–412 MBq/mg) at the time of injection. Sequential whole-body PET/CT imaging was performed 1, 2, and 4 h after injection of 18F-ASIS. Patients were monitored for changes in vital signs, electrocardiograms, and blood parameters before and after radiotracer administration. Adverse events were registered up to 48 h after administration of 18F-ASIS and coded according to the Common Terminology Criteria for Adverse Events (version 5.0). Blood sampling and urine collection was performed for pharmacokinetic analyses. The study design is summarized in Figure 1. A detailed study description is provided in the supplemental information (supplemental materials are available at http://jnm.snmjournals.org). When available, tumor biopsies or surgically excised primary tumor tissue and local lymph nodes were collected, and TF expression was analyzed with immunohistochemistry and enzyme-linked immunosorbent assay (ELISA).

Inhibition of FVIIa

FVIIa (Novo Nordisk A/S) was dissolved in water and 5 equivalents of α-Phe-Phe-Arg-chloromethyl ketone (fFR-cmk; Bachem) were added for inhibition of FVIIa to produce ASIS. After inhibition (1 h, 4°C), excess of inhibitor was removed by dialysis (Slide-a-lyzer, MWCO 10; Thermo Fisher Scientific) in 50 mM N-2-hydroxyethylpiperazine-N’-2-ethanesulfonic acid (HEPES, 150 mM NaCl, 10 mM CaCl2, pH 7.4; Sigma-Aldrich) overnight. The content of fFR-cmk and the concentration of ASIS were analyzed by high-pressure liquid chromatograph (HPLC) using an Aeris C4 column (3.6 μm, 150 × 4.6 mm; Phenomenex) and 1.5 mL/min solvent flow with a gradient method: 0–2 min 17% B, 2–5 min 60% B, 5–6 min 60% B, 6–7 min 17% B, 7–8 min 17% B with solvent phases 0.1% trifluoroacetic acid (TFA) in H2O (A) and 0.1% TFA in acetonitrile (MeCN) (B). Aliquots (500 μL) were stored at −80°C before labeling.

Synthesis of 18F-ASIS

ASIS was labeled with the 18F-containing prosthetic group 18F-SFB. 18F-SFB was produced in a 3-step, 1-pot synthesis on a qualified Tracer-LabEX module (GE Healthcare) with a final solid-phase extraction purification in 80% MeCN. 18F-SFB was subsequently evaporated to dryness in a single vial. ASIS (500 μL) was added to the vial for labeling at room temperature for 30 min followed by purification with a PD10 column (Sigma-Aldrich) into formulation buffer (10 mM GlyGly, 150 mM NaCl, and 10 mM CaCl2, pH 7.5). The final product was sterile-filtered in a laminar airflow bench, and a sample was drawn for quality control. The shelf-life of 18F-ASIS was evaluated up to 4 h after the end of synthesis.

Quality Control of 18F-ASIS

All analytic methods were validated according to the International Council of Harmonization guidelines (17). The radiochemical purity, unspecified 18F-labeled impurities, and 18F-fluoride were determined with radio-HPLC, and the content of ASIS was determined by ultra-violet detector HPLC; both using the same gradients as described in the “Inhibition of FVIIa” section. Residual MeCN from the 18F-SFB synthesis was determined by gas chromatography. Color spot tests were used to determine the content of tetrabutylammonium hydrogen carbonate and HEPES in the final product. The immunoreactivity of 18F-ASIS was determined by Lindmo assay using a high TF-expressing cell line (BxPC-3, CRL-1687; American Type Culture Collection) according to previously described procedures (18). Quality control parameters are summarized in Supplemental Table 1.

Plasma and Urine Pharmacokinetics

The activity of urine, whole blood, and plasma samples was measured on a Cobra II TM γ-Counter (Packard). The plasma samples were prepared from whole-blood samples by centrifugation (3,500 rpm, 4 min) and filtering of the supernatant plasma through a 0.45-μM syringe filter. The radiotracer plasma half-life was determined from the activity concentrations in plasma decay-corrected to the blood sampling time points (approximately 1, 2, and 4 h after injection). The accumulated percentages of excreted radiotracer in urine were determined from the ratio between the accumulated activity in urine and the injected radiotracer activity dose decay-corrected to the urine sampling time points (approximately 1, 2, and 5 h after injection). Metabolites in plasma and urine samples were analyzed by radio-HPLC with a PosiRAM Module (LabLogic) 4 using the same gradients as described in the “Inhibition of FVIIa” section.
Image Acquisition

Images were acquired on a Biograph 128 mCT PET/CT (Siemens Healthineers) with PET acquisition commenced 1, 2, and 4 h after injection of $^{18}$F-ASIS. Unless otherwise contraindicated, patients were injected with intravenous iodine-based contrast (Optiray [Guerbet] 300 mg I/mL, 70–100 mL, injection rate 1.5–2.5 mL/s) using an automated Medrad Stellant injection system (Bayer). Detailed descriptions of the PET and CT imaging parameters (including acquisition times and reconstruction parameters) are provided in the supplemental materials.

Biodistribution and Dosimetry

Dosimetry was based on the PET images ($n = 10$) supplemented with sampled urine data ($n = 8$). For each patient, organ, and time point, tissue activity concentration was calculated as the average of the mean values from 3 volumes of interests drawn in the following organs/regions: adrenal, bone, brain, blood pool, ascending and descending colon, heart wall, kidney, liver, lung, red marrow (L3–L5 vertebrae), small intestines, spleen, stomach contents, and thyroid using MIRADA DBx, version 1.2.0 (Mirada Medical). OLINDA/EXM 2.0 software (Vanderbilt University and HERMES Medical Solutions) was used for calculation of dosimetry parameters using the organ masses of the OLINDA male adult phantom ($^{19}$, $^{20}$) and the absorbed doses for organs and effective dose with tissue-weighting factors according to International Commission on Radiological Protection (ICRP) 103 ($^{21}$). A detailed description of the dosimetry calculation and biodistribution data processing is provided in the supplemental materials.

Image Analysis

The PET/CT images were evaluated by a highly experienced team consisting of a nuclear medicine specialist and a radiologist. Size measurements of the primary tumor and metastases (if any) were performed on the diagnostic CT. In tumor lesions identified on the CT, radiotracer accumulation was measured on the PET images and reported as SUVs.

TABLE 1

Patient Characteristics

<table>
<thead>
<tr>
<th>Patient</th>
<th>Sex</th>
<th>Age (y)</th>
<th>Primary tumor (type [stage])</th>
<th>Prior cancer treatment</th>
<th>Concomitant cancer treatment</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>Female</td>
<td>88</td>
<td>Pancreas PT: DAC [pT2N0M0]</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>2</td>
<td>Female</td>
<td>67</td>
<td>Pancreas PT: DAC [pT2N0M0]</td>
<td>None</td>
<td>CTX</td>
</tr>
<tr>
<td>3</td>
<td>Female</td>
<td>69</td>
<td>Pancreas PT: PAC [pT2bN0M0]</td>
<td>CTX</td>
<td>None</td>
</tr>
<tr>
<td>4</td>
<td>Female</td>
<td>54</td>
<td>Pancreas PT: ILC [pT2N0M0]</td>
<td>CTX</td>
<td>None</td>
</tr>
<tr>
<td>5</td>
<td>Male</td>
<td>65</td>
<td>Lung† PT: DAC [pT2N0M0]</td>
<td>CTX</td>
<td>None</td>
</tr>
<tr>
<td>6</td>
<td>Female</td>
<td>58</td>
<td>Breast AC</td>
<td>CTX</td>
<td>None</td>
</tr>
<tr>
<td>7</td>
<td>Female</td>
<td>54</td>
<td>Breast AC</td>
<td>CTX</td>
<td>None</td>
</tr>
<tr>
<td>8</td>
<td>Female</td>
<td>59</td>
<td>Cervix AC</td>
<td>CTX</td>
<td>None</td>
</tr>
<tr>
<td>9</td>
<td>Female</td>
<td>43</td>
<td>Breast AC</td>
<td>CTX</td>
<td>None</td>
</tr>
<tr>
<td>10</td>
<td>Female</td>
<td>73</td>
<td>Breast AC</td>
<td>CTX</td>
<td>None</td>
</tr>
</tbody>
</table>

*Pathology TNM staging is reported in square brackets when available.†Primary tumor removed.‡Two separate tumors without connection: Tumor 1: HER2+/ER100%; Tumor 2: HER2−/ER100%.

FIGURE 2. Representative maximum-intensity projection showing distribution of $^{18}$F-ASIS for patient 5.
Spheric volumes of interest maximizing a volume encompassed by the tumor lesion perimeter based on the CT images were used for uptake quantification, and the tumor lesion SUV$_{\text{max}}$ and SUV$_{\text{mean}}$ were recorded on the PET images. Tumor-to-blood ratios were calculated as tumor lesion SUV$_{\text{max}}$ divided by the blood pool SUV$_{\text{mean}}$. Any additional foci identified only on PET, judged indicative of a primary tumor or metastases by the readers, were recorded. SyngoVIA (version VB30A-HF04; Siemens Healthineers) was used for the image analysis.

**RESULTS**

**Radiochemistry**

$^{18}$F-SFB was prepared in 29.4% $\pm$ 25.9% non-decay-corrected radiochemical yield ($n$ = 10 batches). $^{18}$F-ASIS was achieved in 221 $\pm$ 58 MBq non-decay-corrected activity yield ($n$ = 10 batches). $^{18}$F-ASIS was produced with a radiochemical purity $\geq$ 95%, and unspecified $^{18}$F-labeled impurities and $^{18}$F-fluoride were both determined to be $\leq$2%. The concentration of ASIS was 0.08 $\pm$ 0.01 mg/mL. Tetrabutylammonium hydrogen carbonate and HEPES content were determined to be 2%. The concentration of ASIS was 0.08 $\pm$ 0.01 mg/mL. Tetrabutylammonium hydrogen carbonate and HEPES content were considered statistically significant.

**Patient Characteristics and Safety**

The characteristics of the patients are shown in Table 1. There were no adverse events and no clinically significant changes in vital signs (Supplemental Table 2), blood parameters (Supplemental Table 3), or electrocardiograms observed in any of the 10 patients.

**Biodistribution, Pharmacokinetics, and Dosimetry**

**Biodistribution.** A representative imaging series demonstrating the radiotracer distribution on the 1-, 2-, and 4-h PET on the maximum-intensity projection is shown in Figure 2 for patient 5. The maximum-intensity projections for the additional 9 patients are presented in Figure 4B. The highest uptake was observed in the urinary bladder followed by the kidneys and the liver. The brain, bone, muscle, red bone marrow, and lung had low and decreasing uptake, suggesting no radiotracer accumulation.

**Pharmacokinetics and Dosimetry.** Time–activity curves measured in plasma ($n$ = 8) are shown in Figure 4A. The plasma half-life was 3.2 $\pm$ 0.6 h. Urinary excretion accounted for most of the $^{18}$F-ASIS elimination, and more than 40% of the injected dose was excreted in urine ($\pi$ = 8). Monoexponential fitting to the decay-corrected time–activity curves in plasma ($n$ = 8). The relationship between the 4-h PET tumor SUV$_{\text{max}}$ and ex vivo measurements of TF expression by ELISA was analyzed with Pearson correlation ($n$ = 5).

**Statistical Methods**

The radiotracer plasma half-life was determined from monoexponential linear regression models (1-compartment models) fitted to the decay-corrected time–activity curves in plasma ($n$ = 8). The relationship between the 4-h PET tumor SUV$_{\text{max}}$ and ex vivo measurements of TF expression by ELISA was analyzed with Pearson correlation ($n$ = 5). Two-sided $P$ values of less than 0.05 were considered statistically significant. Data are presented as mean $\pm$ SD unless otherwise noted. All statistical analyses were performed using R, version 3.6.1 (R Foundation for Statistical Computing).
activity was accumulated in the urine within 5 h after injection (Fig. 4B). Radio-HPLC run on plasma samples showed no major metabolites. Radio-HPLC run on urine samples showed urinary excretion of a smaller 18F-radiolabeled fragment, suggesting renal metabolism of 18F-ASIS. Representative chromatograms of plasma samples collected 1, 2, and 4 h after injection and urine samples collected 1, 2, and 5 h after injection are shown in Figure 4C. The dosimetry output from the OLINDA/EXM dosimetry software is shown in Table 2. The highest dose was received by the urinary bladder wall (118 mGy/MBq) followed by the kidneys (76 mGy/MBq), liver (67 mGy/MBq), and spleen (60 mGy/MBq). The effective dose was 20 mSv/MBq corresponding to 4 mSv for a target activity of 200 MBq.

**Radiotracer Accumulation in Tumor and Correlation with Ex Vivo Tumor Tissue**

18F-ASIS accumulation in tumor lesions quantified as SUV max and tumor-to-blood ratios are shown in Figure 5. Heterogeneous SUV max patterns between patients were observed: for patients 3 and 4 (both primary pancreatic tumors) and 5 (lung metastasis) SUV max increased on the 2- to 4-h PET compared with the 1-h PET. Contrary, in patients 7 and 8 (both primary breast tumors), low uptake was observed at all 3 time points. The remaining patients showed relatively intermediate SUV max that remained stable or slightly increased with time. Compared with the other patients, for patients 3 and 4 the 4-h PET SUV max was relatively high. The tumor-to-blood ratios showed a similar pattern.

Within tumor and within patient heterogeneity in radiotracer accumulation was also observed. Patient 10 (breast cancer) had heterogeneous radiotracer accumulation in the primary tumor (Fig. 6A), with 4-h PET SUV max in the intermediate range (2.86).
A corresponding small tissue sample taken immediately from the surgically resected tumor showed low ex vivo TF expression measured with both ELISA and immunohistochemistry (Fig. 6B). However, TF immunohistochemistry staining of the tumor from the full mastectomy specimen, performed after the pathology examination, showed areas with intermediate TF expression (Fig. 6C). The pathology examination demonstrated 2 separate primary tumors. This patient also had an axially sentinel node metastasis that was not enlarged on CT, showed no apparent focal accumulation on PET, and had low TF expression on immunohistochemistry (Fig. 6D).

There was a trend of a positive correlation between 4-h PET SUV$_{\text{max}}$ and TF expression measured ex vivo on matched tumor tissue samples, although not statistically significant ($r = 0.84$, $P = 0.08$, $n = 5$). TF immunohistochemistry stains in matched tumor tissue samples were available for 7 patients. Representative examples of low, intermediate, and high TF expression on immunohistochemistry with corresponding 4-h PET/CT images are shown in Figure 7. A summary of the PET/CT findings, quantitative plasma and ex vivo tumor TF expression, and TF immunohistochemistry staining patterns is shown in Table 3.

**DISCUSSION**

We report here the first-in-humans experience of the TF-targeted radiotracer $^{18}$F-ASIS in cancer patients. The trial marks the first test in humans of a PET radiotracer targeting TF (first-in-class). Our main finding was that injection of $^{18}$F-ASIS was safe, and no adverse events were observed. The effective radiation dose of 4 mSv from administration of 200 MBq of $^{18}$F-ASIS is lower than that received after a standard $^{18}$F-FDG injection (22). None of the calculated organ-specific absorbed doses were prohibitive for administration of 200 MBq of $^{18}$F-ASIS. As an indication of the specific tumor-targeting ability of $^{18}$F-ASIS, we observed a trend of a positive correlation between tumor SUV$_{\text{max}}$ and quantitative TF expression determined ex vivo ($r = 0.84$, $P = 0.08$). These initial findings represent important first steps toward the clinical implementation of $^{18}$F-ASIS PET imaging as a companion diagnostic tool for TF-targeted therapies.

The biodistribution and pharmacokinetic data indicated that the primary elimination route of $^{18}$F-ASIS was through the kidneys. The low bone uptake is supportive of high metabolic stability, as freely circulating $^{18}$F-fluoride would expectedly result in high bone accumulation (23). The 3.2-h $^{18}$F-ASIS plasma half-life was comparable to the 3.8-h plasma half-life observed for an unlabeled version of ASIS at similar dose (24), suggesting that the radiolabeling does not fundamentally alter the elimination of the radiotracer from plasma. Compared with antibody- and antibody fragment–based TF-targeted radiotracers with long circulation time resulting in optimal tumor-to-background contrast after several days in preclinical

---

**FIGURE 7.** (A) Patient 7: breast tumor with low 4-h PET SUV$_{\text{max}}$ (0.69) and low TF expression on immunohistochemistry ex vivo. (B) Patient 2: pancreatic tumor with relatively intermediate 4-h PET SUV$_{\text{max}}$ (1.79) and intermediate TF expression on immunohistochemistry. (C) Patient 4: pancreatic tumor with relatively high 4-h PET SUV$_{\text{max}}$ (4.71) and high TF expression on immunohistochemistry. Images from top to bottom are: 4-h CT, PET and fused PET/CT, and immunohistochemistry. Arrows mark tumor location on PET/CT.
### TABLE 3
PET/CT Image Findings and Ex Vivo Tissue Factor Measurements

<table>
<thead>
<tr>
<th>Characteristic</th>
<th>1</th>
<th>2</th>
<th>3</th>
<th>4</th>
<th>5</th>
<th>6</th>
<th>7</th>
<th>8</th>
<th>9</th>
<th>10</th>
</tr>
</thead>
<tbody>
<tr>
<td>Primary tumor</td>
<td>Pancreas</td>
<td>Pancreas</td>
<td>Pancreas</td>
<td>Pancreas</td>
<td>Lung</td>
<td>Lung</td>
<td>Breast</td>
<td>Breast</td>
<td>Cervix</td>
<td>Breast</td>
</tr>
<tr>
<td>Radiotracer mass (mg)</td>
<td>0.84</td>
<td>0.69</td>
<td>0.71</td>
<td>0.71</td>
<td>0.74</td>
<td>0.41</td>
<td>0.76</td>
<td>0.56</td>
<td>0.74</td>
<td>0.58</td>
</tr>
<tr>
<td>Injected activity (MBq)</td>
<td>135</td>
<td>187</td>
<td>198</td>
<td>189</td>
<td>93</td>
<td>169</td>
<td>145</td>
<td>187</td>
<td>117</td>
<td>145</td>
</tr>
<tr>
<td>Specific activity* (MBq/mg)</td>
<td>161</td>
<td>271</td>
<td>279</td>
<td>266</td>
<td>126</td>
<td>412</td>
<td>191</td>
<td>334</td>
<td>158</td>
<td>250</td>
</tr>
<tr>
<td>Metastases (Pathology/PET/CT)†</td>
<td>/+/+</td>
<td>/+/+</td>
<td>/+/+</td>
<td>/+/+</td>
<td>/+/+</td>
<td>/+/+</td>
<td>/+/+</td>
<td>/+/+</td>
<td>/+/+</td>
<td>/+/+</td>
</tr>
<tr>
<td>Tumor size (cm)</td>
<td>3.6×3.3</td>
<td>3.5×3.1</td>
<td>4.9×3.8</td>
<td>2.6×2.2</td>
<td>1.2×0.9†</td>
<td>3.6×3.4</td>
<td>2.8×1.4</td>
<td>0.7×0.8</td>
<td>3.2×2.9</td>
<td>2.4×1.4</td>
</tr>
<tr>
<td>Tumor SUV&lt;sub&gt;max&lt;/sub&gt; 1 h</td>
<td>3.04</td>
<td>1.50</td>
<td>3.04</td>
<td>3.45</td>
<td>1.22†</td>
<td>1.82</td>
<td>0.49</td>
<td>0.25</td>
<td>1.37</td>
<td>1.90†</td>
</tr>
<tr>
<td>2 h</td>
<td>2.14</td>
<td>1.74</td>
<td>3.23</td>
<td>4.04</td>
<td>1.81†</td>
<td>1.80</td>
<td>0.31</td>
<td>0.19</td>
<td>1.74</td>
<td>2.18†</td>
</tr>
<tr>
<td>4 h</td>
<td>3.03</td>
<td>1.79</td>
<td>5.44</td>
<td>4.71</td>
<td>3.08†</td>
<td>1.61</td>
<td>0.69</td>
<td>0.25</td>
<td>1.82</td>
<td>2.86†</td>
</tr>
<tr>
<td>Tumor SUV&lt;sub&gt;mean&lt;/sub&gt; 1 h</td>
<td>1.41</td>
<td>0.85</td>
<td>1.67</td>
<td>1.93</td>
<td>0.83†</td>
<td>0.70</td>
<td>0.30</td>
<td>0.20</td>
<td>0.75</td>
<td>1.19†</td>
</tr>
<tr>
<td>2 h</td>
<td>1.38</td>
<td>0.96</td>
<td>1.73</td>
<td>2.24</td>
<td>1.19†</td>
<td>1.26</td>
<td>0.21</td>
<td>0.15</td>
<td>0.92</td>
<td>1.21†</td>
</tr>
<tr>
<td>4 h</td>
<td>1.68</td>
<td>0.98</td>
<td>2.94</td>
<td>2.62</td>
<td>1.97†</td>
<td>1.18</td>
<td>0.40</td>
<td>0.15</td>
<td>1.01</td>
<td>1.73†</td>
</tr>
<tr>
<td>ΔT (d)‡</td>
<td>42</td>
<td>4</td>
<td>NA</td>
<td>6</td>
<td>NA</td>
<td>12</td>
<td>5</td>
<td>6</td>
<td>4</td>
<td></td>
</tr>
<tr>
<td>TF&lt;sub&gt;tumor&lt;/sub&gt; (µg/mg)</td>
<td>NA</td>
<td>5.93</td>
<td>NA</td>
<td>25.75</td>
<td>NA</td>
<td>NA</td>
<td>1.14</td>
<td>NA</td>
<td>1.27** PT: 0.67 MET: NA</td>
<td></td>
</tr>
<tr>
<td>TF&lt;sub&gt;tumor&lt;/sub&gt; IHC§</td>
<td>Low** Intermediate NA High NA NA Low Low Low** PT: Low/ intermediate††</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>TF&lt;sub&gt;plasma&lt;/sub&gt; (µg/L)</td>
<td>61</td>
<td>54</td>
<td>56</td>
<td>72</td>
<td>73</td>
<td>43</td>
<td>82</td>
<td>66</td>
<td>21</td>
<td>73</td>
</tr>
</tbody>
</table>

*At time of injection.
†Presence of metastases based on pathology, PET, and CT, respectively.
‡Time between imaging and tissue collection.
§TF expression on immunohistochemistry (IHC) rated low, intermediate, or high based on visual assessment.
†Primary tumor removed. SUV and size measured on metastasis.
¶No lymph node enlargement on CT and no apparent focal accumulation on PET.
††Heterogeneous radiotracer accumulation observed.
**Samples from biopsies.
††Low TF staining on IHC on tissue sample also showing low (0.67 µg/mg) TF expression. Tissue from full mastectomy, obtained from postpathology evaluation, with intermediate TF expression on IHC.

+ = metastases present; † = no metastases; MET = metastases; NA = not available; PT = primary tumor.
Conclusions should not, of course, be inferred from single observations, with no apparent focal PET accumulation, had low TF expression on tantalently, the sentinel node metastasis without enlargement on CT, and could be otherwise missed on a biopsy is possible with PET. Important the whole-body tumor burden, identifying the potential of PET imaging for evaluation of TF expression. As PET imaging captures the whole-body tumor burden, identification of hotspots that could be otherwise missed on a biopsy is possible with PET. Importantly, the sentinel node metastasis without enlargement on CT, and with no apparent focal PET accumulation, had low TF expression on immunohistochemistry, which suggests that PET was not false-negative. Conclusions should not, of course, be inferred from single observations, but the results encourage further investigation.

The trend of a positive correlation between tumor SUV$_{\text{max}}$ and quantitative TF expression measured ex vivo ($r = 0.84, P = 0.08$) suggests that $^{18}$F-ASIS accumulation depends on the levels of TF in tumors. It may be argued that the radiotracer accumulation in tumors was modest. Importantly, this does not pose a limitation to the use of $^{18}$F-ASIS PET as a whole-body noninvasive companion diagnostic or prognostic tool based on tumor TF expression if robust correlations between PET-derived tumor radiotracer accumulation and actual TF expression can be established. The relationship between SUV$_{\text{max}}$ and ex vivo TF expression presented in this study suggests such a correlation. The observed trend is in line with our preclinical results in xenografted mouse models that showed a strong and statistically significant positive correlation between tumor SUV$_{\text{max}}$ on 4-h $^{18}$F-ASIS PET and TF expression measured in excised tumor tissue (16). The specificity of $^{18}$F-ASIS for targeting TF was supported by the qualitative relationship between the tumor SUV$_{\text{max}}$ and TF immunohistochemistry staining patterns of surgical specimens that generally were in agreement. These preliminary results suggest that $^{18}$F-ASIS PET imaging can be used for noninvasive measurement of TF expression in tumor tissues, which may ultimately assist in identifying patients eligible for TF-targeted therapies. However, future later-phase clinical studies are needed to validate these findings in larger populations.

**CONCLUSION**

$^{18}$F-ASIS can safely be administered to cancer patients for TF-targeted PET imaging. The trial marks the first test of a TF-targeted PET radiotracer in humans (first-in-class). The effective whole-body dose from injection of 200 MBq was 4 mSv and no prohibitive organ-specific absorbed doses were observed. Plasma half-life was 3.2 h, and renal elimination accounted for most of the radiotracer excretion. The findings represent important first steps toward the clinical implementation of $^{18}$F-ASIS for PET imaging of TF expression, which could assist in patient prognostication and selection of eligible patients for TF-targeted therapies. Future later-phase studies are needed to validate these initial findings.

**DISCLOSURE**

This project received funding from the European Union’s Horizon 2020 research and innovation program under grant agreements no. 670261 (ERC Advanced Grant) and 668532 (Click-It), the Lundbeck Foundation, the Novo Nordisk Foundation, the Innovation Fund Denmark, the Danish Cancer Society, Arvid Nilsson Foundation, the Nyede Foundation, the Research Foundation of Rigshospitalet, the Danish National Research Foundation (grant 126), the Research Council of the Capital Region of Denmark, the Danish Health Authority, the John and Birthe Meyer Foundation and Research Council for Independent Research. Andreas Kjaer and Carsten H. Nielsen are inventors/hold intellectual property rights on a patent covering tissue factor imaging. Andreas Kjaer is a Lundbeck Foundation Professor. No other potential conflict of interest relevant to this article was reported.

**ACKNOWLEDGMENTS**

We are grateful to the staff at the Department of Clinical Physiology and Nuclear Medicine for help with performing the PET/CT studies and for the patients for participating in the study. We also thank Katrine Qvist for performing the ex vivo immunohistochemistry staining and ELISA measurements. Novo Nordisk A/S is gratefully acknowledged for providing GMP-grade FVIIa.

**KEY POINTS**

**QUESTION:** Can $^{18}$F-ASIS safely be administered to cancer patients for PET imaging of TF in tumors?

**PERTINENT FINDINGS:** In this first-in-humans clinical trial of 10 cancer patients, administration of $^{18}$F-ASIS was safe, and no adverse events were reported. The effective whole-body dose was 4 mSv for injection of a target activity of 200 MBq, and no prohibitive organ-specific absorbed doses were observed.

**IMPLICATIONS FOR PATIENT CARE:** The trial marks the first test in humans of a PET radiotracer targeting TF (first-in-class). The findings represent important first steps toward implementation of $^{18}$F-ASIS PET imaging of TF in cancer patients for prognostication and selection of patients for TF-targeted therapies.

**REFERENCES**


